Quotient Sciences in the news

Quotient Sciences and Acesion Pharma partnered to use AI-enhanced formulation development for cardiac arrhythmia treatments, accelerating drug development.

Quotient Sciences and Acesion Pharma are collaborating to integrate AI-enhanced formulation technology with Quotient Sciences' Translational Pharmaceutics platform to accelerate drug development for Acesion's atrial fibrillation pipeline.

Quotient Sciences developed and tested an AI-guided drug formulation method to accelerate drug development by optimizing modified-release compositions based on clinical trial data.

Quotient Sciences' AI algorithm successfully optimized drug formulation and dosage in a clinical study, significantly reducing development time.

A webinar by Quotient Sciences and NGT Biopharma Consultants, hosted by Xtalks, will discuss strategies to improve drug solubility from formulation to scale-up.

The webinar by Quotient Sciences and NGT Biopharma Consultants will discuss integrated formulation strategies to improve drug solubility from early development through clinical supply.

Quotient Sciences and NGT Biopharma Consultants are hosting a webinar on improving drug solubility in drug development through integrated formulation strategies.

Quotient Sciences Ltd.'s global employee count decreased by 7.4% from 1,177 in 2023 to approximately 1,090 by March 2026.

Dosing patients with an AI-formulated drug in a Phase I trial moves artificial intelligence from theoretical modeling into practical clinical application.

Phase I clinical testing has begun for a drug formulation designed by artificial intelligence to accelerate pharmaceutical development timelines.

Artificial intelligence is rapidly accelerating drug development timelines and optimizing formulation processes through data-driven approaches and strategic partnerships, while regulators establish guidelines for safe and effective integration.

Quotient Sciences has started a Phase I clinical study in the UK for a novel oral drug formulation developed using artificial intelligence.

Nottingham-based Quotient Sciences has started a Phase I clinical trial for an AI-designed oral drug formulation following MHRA approval.

A Phase I clinical trial has been initiated to evaluate the safety and performance of a drug formulation developed through AI and machine learning algorithms.

An AI-designed drug formulation has entered a Phase I clinical study to validate machine learning's ability to accelerate pharmaceutical development.

The company has launched a Phase I clinical trial for a drug product designed using artificial intelligence to speed up the formulation process.

Quotient Sciences Ltd. has 1,042 employees with a 1.0% year-over-year growth rate.

A strategic partnership with Intrepid Labs integrates the ANDROMEDA AI platform into pharmaceutical development to accelerate drug formulation and clinical testing success.

Expanded commercial supply agreement with Ipsen to manufacture a niche treatment for an ultra-rare genetic disease.

Lindus Health and Quotient Sciences are partnering to create a single-supplier pathway for biotech companies moving from early-stage to pivotal clinical trials.